Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1185

Allergy Therapeutics plc (AGY) - Financial and Strategic SWOT Analysis Review

Allergy Therapeutics plc (AGY) - Financial and Strategic SWOT Analysis Review

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $125.00
Meta Description Allergy Therapeutics plc (Allergy Therapeutics) is a specialty pharmaceutical company. It develops diagnosis and treatment of allergy. The product pipeline of the company comprises allergy vaccines in Phase II and Phase III clinical development and few ar
Publisher GlobalData
Date of Report Dec 3, 2013
Quick Overview
Summary

Allergy Therapeutics plc (Allergy Therapeutics) is a specialty pharmaceutical company. It develops diagnosis and treatment of allergy. The product pipeline of the company comprises allergy vaccines in Phase II and Phase III clinical development and few are in preclinical Phase. Its developmental stage products include, Japanese Cedar, Sublingual MPL, Trees and Grasses. The marketed products in the product portfolio of the company contains tyrosine depot, allergoids (modified allergens) and MPL adjuvant. Allergy Therapeutics lead product Pollinex Quattro is an injectable short course vaccine for allergic conditions. The other products of the company are TA Mix top, Pollinex and Venomil.

Allergy Therapeutics plc Key Recent Developments

Sep 14, 2012: Allergy Therapeutics Reports Revenue Of £41.3m In Fiscal 2012nMay 23, 2012: Lincoln Medical Provides Notification On Voluntary Recall Of Anapen
Mar 30, 2012: Allergy Therapeutics Reports Revenue Of £28.5m In H1 Fiscal 2012GDPH57668FSA

This comprehensive SWOT profile of Allergy Therapeutics plc provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Allergy Therapeutics plc - Key Facts 5
Allergy Therapeutics plc - Key Employees 6
Allergy Therapeutics plc - Key Employee Biographies 7
Allergy Therapeutics plc - Major Products and Services 8
Allergy Therapeutics plc - Pharmaceutical Pipeline Products Data 9
Allergy Therapeutics plc, Pipeline Products by Therapy Area 9
Allergy Therapeutics plc, Pipeline Products by Development Phase 10
Allergy Therapeutics plc - History 12
Allergy Therapeutics plc - Company Statement 14
Allergy Therapeutics plc - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 – Company Analysis 17
Allergy Therapeutics plc - Business Description 17
Allergy Therapeutics plc - Corporate Strategy 18
Allergy Therapeutics plc - SWOT Analysis 19
SWOT Analysis - Overview 19
Allergy Therapeutics plc - Strengths 19
Strength - Increasing Operational Efficiency 19
Strength - Sturdy Research and Development Activities 19
Strength - Product Pipeline 19
Allergy Therapeutics plc - Weaknesses 20
Weakness - Dependence on Germany 20
Weakness - Increasing Trade Receivables 20
Allergy Therapeutics plc - Opportunities 20
Opportunity - Market Potential: Inflammatory Diseases 20
Opportunity - Emerging Markets 20
Opportunity - Potential Immunotherapy Market 20
Allergy Therapeutics plc - Threats 21
Threat - Uncertain R&D Outcomes 21
Threat - Tightening of FDA’s Regulatory Oversight 21
Threat - Intense Competition 21
Allergy Therapeutics plc - Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios - Capital Market Ratios 23
Financial Ratios - Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios - Interim Ratios 26
Financial Ratios - Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Allergy Therapeutics plc, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 28
Allergy Therapeutics plc, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 29
Allergy Therapeutics plc, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Allergy Therapeutics plc, Recent Developments 31
Sep 14, 2012: Allergy Therapeutics Reports Revenue Of £41.3m In Fiscal 2012 31
May 23, 2012: Lincoln Medical Provides Notification On Voluntary Recall Of Anapen 31
Mar 30, 2012: Allergy Therapeutics Reports Revenue Of £28.5m In H1 Fiscal 2012 31
Section 6 – Appendix 32
Methodology 32
Ratio Definitions 32
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Allergy Therapeutics plc, Key Facts 5
Allergy Therapeutics plc, Key Employees 6
Allergy Therapeutics plc, Key Employee Biographies 7
Allergy Therapeutics plc, Major Products and Services 8
Allergy Therapeutics plc, Number of Pipeline Products by Therapy Area 9
Allergy Therapeutics plc, Number of Pipeline Products by Development Stage 10
Allergy Therapeutics plc, Pipeline Products By Therapy Area and Development Phase 11
Allergy Therapeutics plc, History 12
Allergy Therapeutics plc, Subsidiaries 16
Allergy Therapeutics plc, Key Competitors 22
Allergy Therapeutics plc, Ratios based on current share price 23
Allergy Therapeutics plc, Annual Ratios 23
Allergy Therapeutics plc, Interim Ratios 26
Allergy Therapeutics plc, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 28
Allergy Therapeutics plc, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 29
Allergy Therapeutics plc, Recent Deals Summary 30
Currency Codes 32
Capital Market Ratios 32
Equity Ratios 33
Profitability Ratios 33
Cost Ratios 34
Liquidity Ratios 34
Leverage Ratios 35
Efficiency Ratios 35

List of Figures
Allergy Therapeutics plc, Pipeline Products by Therapy Area 9
Allergy Therapeutics plc, Pipeline Products by Development Phase 10
Allergy Therapeutics plc, Performance Chart (2008 - 2012) 25
Allergy Therapeutics plc, Ratio Charts 27
Allergy Therapeutics plc, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 28
Allergy Therapeutics plc, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 29




...